Tonix Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced the appointment of David L. Grange as its new General Counsel. Grange, who joins from Lowenstein Sandler LLP, brings extensive legal expertise to his new role, having advised clients across various sectors on regulatory and transactional matters. His experience is seen as a strategic fit for Tonix as it advances its portfolio of immunology, pain management, and antiviral products.
Prior to joining Tonix, Grange was a partner at Lowenstein Sandler, where he specialized in corporate law with a focus on mergers and acquisitions, securities, and compliance. His background is expected to bolster Tonix’s legal department, enhancing its capacity to navigate the complex regulatory landscape that characterizes the biopharmaceutical industry, as highlighted in a recent report.
This appointment comes at a critical time for Tonix, which is actively engaged in developing treatments for conditions such as fibromyalgia and COVID-19. The company’s ongoing research and development efforts require a robust legal framework to manage partnerships, intellectual property rights, and compliance with federal regulations. Grange’s expertise could prove instrumental in solidifying these aspects and supporting Tonix’s strategic goals.
Tonix has made significant strides in its clinical trials over the past year. The company recently announced positive data from its mid-phase trial for a fibromyalgia treatment, setting the stage for further development. The addition of Grange to the executive team is likely to facilitate the legal oversight necessary for such advancements. Moreover, with growing pressure on pharmaceutical companies to ensure transparency and cooperation with regulatory bodies, having a seasoned legal figure in-house could offer Tonix greater agility and risk management capabilities.
As Tonix continues to navigate a highly competitive industry, the comprehensive legal leadership provided by Grange could have far-reaching implications. Ensuring compliance and fostering innovation are crucial in maintaining a competitive edge in the biopharmaceutical sector, and Tonix’s strategic appointment reflects these priorities.